<DOC>
	<DOCNO>NCT00763893</DOCNO>
	<brief_summary>The purpose study evaluate losartan limit aortic dilatation patient Marfan syndrome .</brief_summary>
	<brief_title>Study Efficacy Losartan Aortic Dilatation Patients With Marfan Syndrome</brief_title>
	<detailed_description>Aim : evaluate efficacy losartan limit aortic dilatation patient marfan syndrome receive standard therapy Inclusion criterion : 10 year old Marfan syndrome accord international criterion Signed informed consent Non inclusion : Previous surgery ascend aorta , surgery plan Non echogenicity Contre-indication lactose Pregnancy go plan within 3 year Breast feeding Participation another clinical study Non member social security CMU Number subject : number subject ( 150 per group ) derive study Shores et al ( 1994 ) demonstrate benefit beta-blockade Marfan patient use decrease half aortic dilatation losartan Follow-up 3 year , inclusion period 2 year . A total 5 year expect Methods : randomise double blind v placebo study . All French centre de competence marfan syndrome centre de reference participate study . End point : main endpoint evolution normalise aortic diameter . Secondary endpoint include clinical event ( cardiac surgery aortic dissection , hospitalisation cardiology department , death ) , tolerance drug , quality life .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Marfan Syndrome</mesh_term>
	<mesh_term>Arachnodactyly</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<criteria>10 year old Marfan syndrome accord international criterion Signed informed consent Previous surgery ascend aorta , surgery plan Non echogenicity Contreindication lactose Pregnancy go plan within 3 year Breast feeding Participation another clinical study Non member social security CMU</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Marfan syndrome</keyword>
	<keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
	<keyword>Aortic Aneurysm , Thoracic</keyword>
</DOC>